Project Grant R01AG095529
- The National Institute on Aging, part of the Department of Health and Human Services National Institutes of Health, awarded $442,750 to the University of California, Davis on September 1, 2026, under the Aging Research program (CFDA 93.866, assistance type: Project Grant) to investigate galectin-12's role in neuroinflammation and Alzheimer's disease progression. The funded research examines how metabolic stress triggers Alzheimer's disease by enhancing inflammation, with a focus on lipid droplet...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded the University of California, Los Angeles $146,750 under the Aging Research program (CFDA 93.866) on July 1, 2026, to identify molecular-neuropathological signatures in Alzheimer's disease, frontotemporal lobar degeneration, and long COVID. The recipient will employ single-cell spatial multi-omics on postmortem brain tissues to characterize molecular and cellular alterations linked to selective...
- The National Institute on Aging awarded the University of California, Davis $586,378 on August 15, 2026, under the Aging Research program (CFDA 93.866) to characterize metabolic and lipidomic signatures of microglia in Alzheimer's disease using spatial metabolomics and lipidomics workflows. The research employs MALDI mass spectrometry imaging combined with highly multiplexed immunofluorescence to provide direct metabolite information of microglia in situ, addressing the heterogeneity of...
- The National Institute on Aging awarded The Leland Stanford Junior University $125,766 on July 1, 2026, under the Aging Research program (CFDA 93.866) to identify molecular mediators linking cardiometabolic risk factors to Alzheimer's disease. The research identifies plasma protein and metabolite mediators of cardiometabolic pathways that contribute to Alzheimer's disease risk using large-scale omics data from the UK Biobank and Million Veteran Program. The project comprises three specific aims:...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $170,668 to the University of California, San Diego on October 24, 2025, under the Aging Research program (CFDA 93.866) to support research into s-nitrosylated phospholipase D3 in Alzheimer's disease pathophysiology. The funded research investigates the mechanistic role of s-nitrosylated phospholipase D3 (SNO-PLD3) in Alzheimer's disease. The work builds on prior mass spectrometry findings that...
- The National Institute on Aging, within the National Institutes of Health and the Department of Health and Human Services, awarded the University of California Irvine $739,365 on September 15, 2026, under the Aging Research program (CFDA 93.866, Project Grant R01AG098878) to develop and evaluate structure-guided active and passive beta-amyloid immunotherapies targeting early, non-fibrillar assemblies in Alzheimer's disease. The project develops vaccines and monoclonal antibodies directed against...
- The National Institute on Aging awarded The Washington University $642,991 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate genetic drivers of phenotypic variability in autosomal dominant Alzheimer's disease using a multi-omics approach. The research identifies genetic alterations associated with Alzheimer's disease risk and presentation in individuals carrying mutations in the PSEN1, APP, and PSEN2 genes. The project characterizes transcriptomic brain profiles...
- The National Institute on Aging awarded the University of California Irvine $636,124 for Project Grant R01AG100345 on September 2, 2026, under the Aging Research program (CFDA 93.866). The award funds multi-omic characterization of molecular pathways driving vulnerability and resilience to Alzheimer's disease in the oldest-old population (age 90 and above). The research employs an integrative multi-omic approach including single-nucleus RNA and ATAC sequencing, spatial transcriptomics, and...
- The National Institute on Aging awarded the University of California, Berkeley $549,260 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop advanced large language model-based AI tools that enhance precision in predicting Alzheimer's disease pathology and cognitive outcomes. The research addresses critical gaps in precision medicine for Alzheimer's disease, particularly the need to capture patient heterogeneity, accurately identify treatment candidates for...
- The National Institute on Aging awarded The Leland Stanford Junior University $251,532 on July 1, 2026, under the Aging Research program (CFDA 93.866) to investigate genetic and proteomic pathways linking Alzheimer's disease to white matter hyperintensities in older adults. The research examines how Alzheimer's disease genetic liability drives white matter hyperintensity burden through circulating protein mediators, with particular focus on African American older adults who carry higher vascular...
The National Institute on Aging, an office of the National Institutes of Health, awarded the University of California, Davis $683,331 under the Aging Research program (CFDA 93.866) on September 1, 2026, to identify and validate causal risk genes and proteins contributing to Alzheimer's disease and its neuropsychiatric symptoms. The research integrates genome-wide association study (GWAS) findings with functional omics data from post-mortem brain tissues to pinpoint proteins mediating Alzheimer's disease and neuropsychiatric symptom pathogenesis. The work has identified 64 brain proteins as causal mediators of Alzheimer's disease GWAS loci, with 8 of these proteins also identified as shared neuropsychiatric symptom risk proteins. Under Aim 1, the recipient will conduct fine-mapping of protein quantitative trait loci (pQTLs) using an existing dataset of 720 human brain proteomes and whole genome sequencing data, then expand to multi-ancestry fine-mapping across 1,086 diverse donors to determine whether putative causal pQTLs are shared or ancestry-specific. Subsequent work will confirm effects of putative causal pQTLs on corresponding protein abundance and test identified risk proteins in model systems to gather orthogonal evidence for their roles in disease pathogenesis. The award runs through May 31, 2031, with performance taking place in California.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $683.3k | 8/27/26 |